Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Evolving Role of the Thoracic Oncologic Surgeon in the Era...
share announcement

Evolving Role of the Thoracic Oncologic Surgeon in the Era of Molecular and Immune-Targeted Therapies for Lung Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (15 September 2023) | Viewed by 4040

Special Issue Editor

Dr. Matthew D. Taylor

E-Mail Website
Guest Editor
Division of Thoracic Surgery, Department of Surgery, Penn State Milton S. Hershey Medical Center, Hershey, PA 17033, USA
Interests: neoplasms; therapeutics; survival; non-small cell lung carcinoma; neoplasm metastasis; lung neoplasms; Ischemia; recurrence; esophageal neoplasms

Special Issue Information

Dear Colleagues, 

The advent of molecular-targeted therapy and immune checkpoint inhibitors has revolutionized the treatment of patients with advanced-stage lung cancer over the past 10 years. Recent promising studies have now begun to investigate the use of immunotherapy and drug-targeted oncogenic driver mutations in patients with operable lung cancer. With the expansion of these treatments to the neoadjuvant setting, it will be critical for the thoracic oncologic surgeon to understand and incorporate preoperative molecular testing and define clinical algorithms aimed at reducing surgical risk in patients who have undergone treatment with molecular targeted therapy and immunotherapy.                

This Special Edition of the Cancers journal will highlight original research and comprehensive reviews related to preoperative tumor molecular characterization, as well as the incorporation of targeted therapy and/or immunotherapy in the treatment of patients with lung cancer undergoing curative resection.   

Dr. Matthew D. Taylor
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung cancer
  • immunotherapy
  • neoadjuvant
  • targeted therapy
  • resection
  • molecular target

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

17 pages, 1486 KiB  
Review
Beyond the Frontline: A Triple-Line Approach of Thoracic Surgeons in Lung Cancer Management—State of the Art
by Benjamin Bottet, Nicolas Piton, Jean Selim, Matthieu Sarsam, Florian Guisier and Jean-Marc Baste
Cancers 2023, 15(16), 4039; https://doi.org/10.3390/cancers15164039 - 09 Aug 2023
Cited by 1 | Viewed by 1277
Abstract
Non-small cell lung cancer (NSCLC) is now described as an extremely heterogeneous disease in its clinical presentation, histology, molecular characteristics, and patient conditions. Over the past 20 years, the management of lung cancer has evolved with positive results. Immune checkpoint inhibitors have revolutionized [...] Read more.
Non-small cell lung cancer (NSCLC) is now described as an extremely heterogeneous disease in its clinical presentation, histology, molecular characteristics, and patient conditions. Over the past 20 years, the management of lung cancer has evolved with positive results. Immune checkpoint inhibitors have revolutionized the treatment landscape for NSCLC in both metastatic and locally advanced stages. The identification of molecular alterations in NSCLC has also allowed the development of targeted therapies, which provide better outcomes than chemotherapy in selected patients. However, patients usually develop acquired resistance to these treatments. On the other hand, thoracic surgery has progressed thanks to minimally invasive procedures, pre-habilitation and enhanced recovery after surgery. Moreover, within thoracic surgery, precision surgery considers the patient and his/her disease in their entirety to offer the best oncologic strategy. Surgeons support patients from pre-operative rehabilitation to surgery and beyond. They are involved in post-treatment follow-up and lung cancer recurrence. When conventional therapies are no longer effective, salvage surgery can be performed on selected patients. Full article
(This article belongs to the Special Issue Evolving Role of the Thoracic Oncologic Surgeon in the Era of Molecular and Immune-Targeted Therapies for Lung Cancer)
►▼ Show Figures

Figure 1

17 pages, 1737 KiB  
Review
Implications of Transglutaminase-Mediated Protein Serotonylation in the Epigenetic Landscape, Small Cell Lung Cancer, and Beyond
by Jason Lin and Shang-Chuen Wu
Cancers 2023, 15(4), 1332; https://doi.org/10.3390/cancers15041332 - 20 Feb 2023
Cited by 2 | Viewed by 2245
Abstract
In the case of small-cell lung carcinoma, the highly metastatic nature of the disease and the propensity for several chromatin modifiers to harbor mutations suggest that epigenetic manipulation may also be a promising route for oncotherapy, but histone deacetylase inhibitors on their own [...] Read more.
In the case of small-cell lung carcinoma, the highly metastatic nature of the disease and the propensity for several chromatin modifiers to harbor mutations suggest that epigenetic manipulation may also be a promising route for oncotherapy, but histone deacetylase inhibitors on their own do not appear to be particularly effective, suggesting that there may be other regulatory parameters that dictate the effectiveness of vorinostat’s reversal of histone deacetylation. Recent discoveries that serotonylation of histone H3 alters the permissibility of gene expression have led to renewed attention to this rare modification, as facilitated by transglutaminase 2, and at the same time introduce new questions about whether this modification belongs to a part of the concerted cohort of regulator events for modulating the epigenetic landscape. This review explores the mechanistic details behind protein serotonylation and its possible connections to the epigenome via histone modifications and glycan interactions and attempts to elucidate the role of transglutaminase 2, such that optimizations to existing histone deacetylase inhibitor designs or combination therapies may be devised for lung and other types of cancer. Full article
(This article belongs to the Special Issue Evolving Role of the Thoracic Oncologic Surgeon in the Era of Molecular and Immune-Targeted Therapies for Lung Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop